Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.
- DOI
- 10.1016/j.smim.2023.101799
- Published
- 2023 Sep
- Container
- Seminars in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.smim.2023.101799,
title = {Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.},
author = {O'Sullivan JA and Youngblood BA and Schleimer RP and Bochner BS},
year = {2023},
journal = {Seminars in immunology},
doi = {10.1016/j.smim.2023.101799},
url = {https://doi.org/10.1016/j.smim.2023.101799}
}RIS
TY - JOUR TI - Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases. AU - O'Sullivan JA AU - Youngblood BA AU - Schleimer RP AU - Bochner BS PY - 2023 JO - Seminars in immunology DO - 10.1016/j.smim.2023.101799 UR - https://doi.org/10.1016/j.smim.2023.101799 ER -
APA
JA, O., BA, Y., RP, S., & BS, B. (2023). Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.. Seminars in immunology. https://doi.org/10.1016/j.smim.2023.101799
Source records
- pubmed · retrieved 2026-09-26T08:16:08.926Z